Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viking Therapeutics

32.07
+0.44001.39%
Post-market: 32.05-0.0200-0.06%19:58 EDT
Volume:3.23M
Turnover:104.30M
Market Cap:3.60B
PE:-27.81
High:32.75
Open:32.20
Low:31.92
Close:31.63
Loading ...

B.Riley Financial Sticks to Its Buy Rating for Viking Therapeutics (VKTX)

TIPRANKS
·
16 Jul

Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?

Zacks
·
09 Jul

Better Growth Buy: Eli Lilly vs. Viking Therapeutics

Motley Fool
·
07 Jul

Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity

Motley Fool
·
04 Jul

Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns. -- Barrons.com

Dow Jones
·
04 Jul

Top Executives at Viking Therapeutics Make Major Stock Moves

TIPRANKS
·
04 Jul

Greg Zante, CFO, Reports Disposal of Common Shares of Viking Therapeutics Inc

Reuters
·
04 Jul

Marianna Mancini, COO of Viking Therapeutics Inc., Reports Disposal of Common Shares

Reuters
·
04 Jul

Viking Therapeutics Inc. Publishes Corporate Presentation Highlighting Advances in Metabolic and Endocrine Disease Therapeutics

Reuters
·
03 Jul

Scotiabank Sticks to Its Buy Rating for Viking Therapeutics (VKTX)

TIPRANKS
·
26 Jun

BTIG ‘encouraged’ by Viking execution, progress in obesity franchise

TIPRANKS
·
26 Jun

Viking Therapeutics (VKTX) Receives a Buy from Morgan Stanley

TIPRANKS
·
26 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Coinbase, Rubrik, AeroVironment

Reuters
·
26 Jun

Viking Therapeutics’ VK2735: A Promising Disruptor in the Obesity Market with Strategic Phase III Trials and Market Appeal

TIPRANKS
·
25 Jun

Viking Therapeutics Price Target Maintained With a $102.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Jun

Viking Therapeutics: Buy Rating Affirmed on Promising VK2735 Trials and Strategic Developments

TIPRANKS
·
25 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Array Technologies, Viking Therapeutics, Winnebago

Reuters
·
25 Jun

BUZZ-Viking Therapeutics rises after it starts late-stage study of obesity drug

Reuters
·
25 Jun

Viking Therapeutics Initiates Phase 3 Clinical Program for Obesity Treatment with Dual Agonist VK2735

Reuters
·
25 Jun

Viking Therapeutics Inc: Expect to Report Results of Phase 2 Venture-Oral Dosing Study in H2

THOMSON REUTERS
·
25 Jun